Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 21

Sort by

Sort Order Select

Journal Articles

Single-cell transcriptomic and clonotypic characterization of Waldenström macroglobulinemia reveals intra-patient monoclonal diversity with distinct differentiation states

Minghao Dang, Sherif Seif, Maria Acevedo-Calado, Linghua Wang, Janelle Sanchez, Lorenzo Gensini, Hima Bansal, Melody Becnel, Mahmoud Gaballa, Hans Lee, Oren Pasvolsky, Krina Patel, Donna Weber, Jing Christine Ye, Robert Orlowski, Sheeba Thomas

Blood (2025) 146 (Supplement 1): 460.

https://doi.org/10.1182/blood-2025-460

Published: 2025

Journal Articles

Molecular profiling and kinetics of circulating multiple myeloma cells (CMMCs) predict resistance to bispecific antibodies (BsAbs) in relapsed and/or refractory multiple myeloma (RRMM)

Blood (2025) 146 (Supplement 1): 4012.

https://doi.org/10.1182/blood-2025-4012

Published: 2025

Journal Articles

Treatment history, not race or duffy-null status, predicts outcomes with teclistamab in Relapsed/Refractory multiple myeloma

Blood (2025) 146 (Supplement 1): 4575.

https://doi.org/10.1182/blood-2025-4575

Published: 2025

Journal Articles

Peripheral blood stem cell collection for patients with multiple myeloma undergoing autologous transplant after quadruplet induction

Blood (2025) 146 (Supplement 1): 7557.

https://doi.org/10.1182/blood-2025-7557

Published: 2025

Journal Articles

Outcomes of bispecific T-cell engagers in MM patients with central nervous system (CNS) involvement

Blood (2025) 146 (Supplement 1): 824.

https://doi.org/10.1182/blood-2025-824

Published: 2025

Journal Articles

BCMA CAR T-cell expansion dynamics and toxicity after idecabtagene vicleucel and ciltacabtagene autoleucel for multiple myeloma

Blood (2025) 146 (Supplement 1): 5850.

https://doi.org/10.1182/blood-2025-5850

Published: 2025

Journal Articles

Final results of a multi-center phase 2 trial of isatuximab-lenalidomide in patients with high risk smoldering multiple myeloma (HRSMM)

Blood (2025) 146 (Supplement 1): 5834.

https://doi.org/10.1182/blood-2025-5834

Published: 2025

Journal Articles

Prognostic impact of CXCR4 mutation type on clinical features and outcomes of patients with Waldenström macroglobulinemia

Anath Lionel, Lorenzo Gensini, Sherif Seif, Wenli Dong, Lei Feng, Janelle Sanchez, Hima Bansal, Melody Becnel, Mahmoud Gaballa, Hans Lee, Oren Pasvolsky, Krina Patel, Jing Christine Ye, Keyur Patel, Donna Weber, Robert Orlowski, Sheeba Thomas

Blood (2025) 146 (Supplement 1): 1829.

https://doi.org/10.1182/blood-2025-1829

Published: 2025

Journal Articles

Simplified frailty score for patients with multiple myeloma undergoing autologous stem cell transplant

Blood (2025) 146 (Supplement 1): 3987.

https://doi.org/10.1182/blood-2025-3987

Published: 2025

Journal Articles

Daratumumab, bortezomib, lenalidomide and dexamethasone, upfront autologous transplant and lenalidomide maintenance for newly diagnosed multiple myeloma

Blood (2025) 146 (Supplement 1): 7509.

https://doi.org/10.1182/blood-2025-7509

Published: 2025

Journal Articles

A Case Control Study of Syngeneic Transplantation Versus Autologous Transplantation for Multiple Myeloma: Two Decades of Experience at MD Anderson

Ghulam Rehman Mohyuddin, MD, Muhammad Salman Faisal, MBBS, Nina Shah, MD, Qaiser Bashir, MD, Chitra Hosing, MD, Krina Patel, MD, Uday R. Popat, MD, Simrit Parmar, MD, Gabriela Rondon, MD, Ruby Delgado, Donna M. Weber, MD, Jatin J. Shah, MD, Sheeba Thomas, MD, Elisabeth E. Manasanch, MD, Robert Z. Orlowski, PhD, MD, Richard E. Champlin, MD, Muzaffar H. Qazilbash, MD

Blood (2016) 128 (22): 4613.

https://doi.org/10.1182/blood.V128.22.4613.4613

Published: 2016

Journal Articles

Gene Expression Profiling Predicts Clinical Outcomes in Newly Diagnosed Multiple Myeloma Patients in a Standard of Care Setting

Catherine M Claussen, MS, Hans Lee, MD, Jatin J. Shah, MD, Tiffany Richards, ANP, Nina Shah, MD, Krina Patel, MD, Qaiser Bashir, MD, Simrit Parmar, MD, Sheeba Thomas, MD, Yago Nieto, MD PhD, Muzaffar H. Qazilbash, MD, Richard Eric Davis, MD, Sattva S. Neelapu, MD, Donna M. Weber, MD, Robert Z. Orlowski, PhD, MD, Lei Feng, MS, Elisabet E. Manasanch, MD

Blood (2016) 128 (22): 5628.

https://doi.org/10.1182/blood.V128.22.5628.5628

Published: 2016

Journal Articles

Use of Gene Expression Profiling May Predict Clinical Outcomes in Newly Diagnosed Multiple Myeloma Patients in a Standard of Care Setting

Catherine M Claussen, MS, Tammy Chuang, Jatin Shah, MD, Hans Lee, MD, Nina Shah, MD, Krina K Patel, Qaiser Bashir, MD, Simrit Parmar, MD, Sheeba Thomas, MD, Muzaffar Qazilbash, MD, Richard Eric Davis, MD, Sattva S. Neelapu, MD, Donna Weber, MD, Robert Z. Orlowski, PhD, MD, Lei Feng, MS, Elisabet E. Manasanch, MD

Blood (2015) 126 (23): 5390.

https://doi.org/10.1182/blood.V126.23.5390.5390

Published: 2015

Journal Articles

Prospective, Multicenter Study of the MTOR Inhibitor Everolimus (RAD001) As Primary Therapy in Waldenstrom's Macroglobulinemia

Steven P Treon, MD, PhD, Christina K Tripsas, Leukothea Ioakimidis, Diane Warren, Christopher Patterson, Leonard Heffner, MD, Herbert Eradat, MD, MS, Stephanie A. Gregory, MD, Sheeba Thomas, MD, Ranjana Advani, MD, Rachid Baz, Ashraf Z. Badros, MD, Jeffrey Matous, MD, Kenneth C. Anderson, MD, Irene M. Ghobrial, MD

Blood (2011) 118 (21): 2951.

https://doi.org/10.1182/blood.V118.21.2951.2951

Published: 2011

Journal Articles

Phase I Trial of the Combination of Lenalidomide, Thalidomide and Dexamethasone In Relapsed/Refractory Multiple Myeloma

Jatin J Shah, MD, Robert Z. Orlowski, MD, PhD, Raymond Alexanian, MD, Michael Wang, MD, Sheeba Thomas, MD, Muzaffar H. Qazilbash, MD, Simrit Parmar, M.D., Nina Shah, MD, Qaiser Bashir, MD, Uday Popat, MD, Donna Weber, MD

Blood (2010) 116 (21): 1948.

https://doi.org/10.1182/blood.V116.21.1948.1948

Published: 2010

Journal Articles

A Phase I/II Trial of the KSP Inhibitor ARRY-520 In Relapsed/Refractory Multiple Myeloma

Jatin J Shah, MD, Jeffrey A. Zonder, MD, Adam Cohen, Donna Weber, MD, Sheeba Thomas, MD, Michael Wang, MD, Jonathan L. Kaufman, MD, Steven Michael Burt, Duncan Walker, Burgess Freeman, Selena Armistead Rush, BS, Ann Ptaszynski, Robert Z. Orlowski, MD, PhD, Sagar Lonial, MD

Blood (2010) 116 (21): 1959.

https://doi.org/10.1182/blood.V116.21.1959.1959

Published: 2010

Journal Articles

Curability of Multiple Myeloma.

Kay B Delasalle, BS, Luhua Wang, MD, Donna Weber, MD, Sergio A. Giralt, MD, Sheeba Thomas, MD, Jatin Shah, MD, Beverly Handy, MD, Robert Z. Orlowski, MD, PhD, Raymond Alexanian, M.D.

Blood (2009) 114 (22): 3864.

https://doi.org/10.1182/blood.V114.22.3864.3864

Published: 2009

Journal Articles

Survival Disparities Between African-American and Caucasian Patients with Multiple Myeloma Are Blunted in the Era of Novel Therapeutics and Autologous Stem Cell Transplantation.

Nina Shah, MD, Donna M Weber, M.D., Michael Wang, MD, Sheeba Thomas, MD, Jatin Shah, MD, Sergio Giralt, MD, Raymond Alexanian, M.D., Robert Z Orlowski, M.D., Ph.D., Muzaffar H. Qazilbash, MD, Tiffany Avery, M.D., MPH

Blood (2009) 114 (22): 1395.

https://doi.org/10.1182/blood.V114.22.1395.1395

Published: 2009

Journal Articles

Reduced-Intensity Regimens for Allogeneic Stem Cell Transplantation Improve the Outcome in Advanced Multiple Myeloma

Suzanne M. Cole, MD, Rima Saliba, Matteo Pelosini, M.D., Floralyn L Mendoza, Donna Weber, MD, Michael Wang, MD, Sheeba Thomas, MD, Robert Z. Orlowski, MD, PhD, Jatin Shah, MD, Amin Alousi, MD, Chitra Hosing, MD, Uday Popat, MD, Partow Kebriaei, MD, Paolo Anderlini, MD, Issa F. Khouri, Richard Champlin, MD, Sergio Giralt, MD, Muzaffar H. Qazilbash, MD

Blood (2008) 112 (11): 3298.

https://doi.org/10.1182/blood.V112.11.3298.3298

Published: 2008

Journal Articles

Retrospective Comparison of Transplant Outcomes in Patients with Multiple Myeloma According to Induction Therapy with Thalidomide/Dexamethasone (TD) with or without Bortezomib (VTD).

Sergio Giralt, MD, Rupi Thandi, MD, Muzaffar Qazilbash, MD, Floralyn Mendoza, BS, Eric Han, BS, Chitra Hosing, MD, Michael Wang, MD, Sheeba Thomas, MD, Raymond Alexanian, MD, Richard Champlin, MD, Donna Weber, MD

Blood (2007) 110 (11): 948.

https://doi.org/10.1182/blood.V110.11.948.948

Published: 2007

Update search

NARROW

Publications

Format

Article Type

Topics

Date

Availability

Single-cell transcriptomic and clonotypic characterization of Waldenström macroglobulinemia reveals intra-patient monoclonal diversity with distinct differentiation states

Molecular profiling and kinetics of circulating multiple myeloma cells (CMMCs) predict resistance to bispecific antibodies (BsAbs) in relapsed and/or refractory multiple myeloma (RRMM)

Treatment history, not race or duffy-null status, predicts outcomes with teclistamab in Relapsed/Refractory multiple myeloma

Peripheral blood stem cell collection for patients with multiple myeloma undergoing autologous transplant after quadruplet induction

Outcomes of bispecific T-cell engagers in MM patients with central nervous system (CNS) involvement

BCMA CAR T-cell expansion dynamics and toxicity after idecabtagene vicleucel and ciltacabtagene autoleucel for multiple myeloma

Final results of a multi-center phase 2 trial of isatuximab-lenalidomide in patients with high risk smoldering multiple myeloma (HRSMM)

Prognostic impact of CXCR4 mutation type on clinical features and outcomes of patients with Waldenström macroglobulinemia

Simplified frailty score for patients with multiple myeloma undergoing autologous stem cell transplant

Daratumumab, bortezomib, lenalidomide and dexamethasone, upfront autologous transplant and lenalidomide maintenance for newly diagnosed multiple myeloma

A Case Control Study of Syngeneic Transplantation Versus Autologous Transplantation for Multiple Myeloma: Two Decades of Experience at MD Anderson

Gene Expression Profiling Predicts Clinical Outcomes in Newly Diagnosed Multiple Myeloma Patients in a Standard of Care Setting

Use of Gene Expression Profiling May Predict Clinical Outcomes in Newly Diagnosed Multiple Myeloma Patients in a Standard of Care Setting

Prospective, Multicenter Study of the MTOR Inhibitor Everolimus (RAD001) As Primary Therapy in Waldenstrom's Macroglobulinemia

Phase I Trial of the Combination of Lenalidomide, Thalidomide and Dexamethasone In Relapsed/Refractory Multiple Myeloma

A Phase I/II Trial of the KSP Inhibitor ARRY-520 In Relapsed/Refractory Multiple Myeloma

Curability of Multiple Myeloma.

Survival Disparities Between African-American and Caucasian Patients with Multiple Myeloma Are Blunted in the Era of Novel Therapeutics and Autologous Stem Cell Transplantation.

Reduced-Intensity Regimens for Allogeneic Stem Cell Transplantation Improve the Outcome in Advanced Multiple Myeloma

Retrospective Comparison of Transplant Outcomes in Patients with Multiple Myeloma According to Induction Therapy with Thalidomide/Dexamethasone (TD) with or without Bortezomib (VTD).

Email alerts

ASH Publications

American Society of Hematology

Update search

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only